Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended September 30, 

​

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Qbrexza®

​

$

5,865

​

$

6,265

​

$

18,038

​

$

19,752

Accutane®

​

 

4,882

​

 

4,121

​

 

15,109

​

 

14,228

Amzeeq®

​

​

2,336

​

​

1,161

​

​

4,904

​

​

5,892

Zilxi®

​

​

681

​

​

554

​

​

1,567

​

​

1,851

Targadox®

​

​

929

​

​

1,168

​

​

2,386

​

​

6,558

Exelderm®

​

 

764

​

 

1,001

​

 

1,813

​

 

3,018

Ximino®

​

​

(199)

​

​

1,773

​

​

567

​

​

3,775

Luxamend®

​

​

21

​

​

—

​

​

21

​

​

—

Total product revenues

​

$

15,279

​

$

16,043

​

$

44,405

​

$

55,074

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended September 30,

 

Nine-Month Periods Ended September 30,

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Non-refundable upfront payment from Maruho

 

$

19,000

 

$

—

​

$

19,000

 

$

—

Net milestone payment from Maruho

​

​

—

​

​

—

​

​

—

​

​

2,500

Royalties on sales of Rapifort® Wipes 2.5%

​

​

260

​

​

73

​

​

519

​

​

129

Total other revenue

​

$

19,260

​

$

73

​

$

19,519

​

$

2,629